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Abstract 
Amardeep Patel 
SYNTHESIS AND CYTOTOXICITY EVALUATION OF FUNCTIONALIZED 
BETULIN DERIVATIVES 
2017-2018 
Subash Jonnalagadda, Ph.D. 
Master of Science in Pharmaceutical Sciences 
 
Betulin and betulinic acid are complex natural compounds that can be readily 
extracted in high quantities from external bark of yellow and white birch trees.  Birch tree 
is native to northern New Jersey and is also commonly available for purchase as 
firewood. Betulinic acid is found to exhibit very good activity against few cancer cell 
lines, and is relatively non-toxic to normal cells.  The ready availability and selective 
cytotoxicity coupled with the favorable therapeutic index have made betulinic acid an 
attractive and promising anticancer agent.  However, this molecule is almost insoluble in 
water and shows anti-cancer activity only on very few cell lines.  
This thesis details our efforts on the development of novel synthetic 
methodologies for the synthesis of functionalized betulin derivatives as potential anti-
cancer agents. We initiated the synthesis of betulin conjugates starting from betulinic acid 
employing reactions such as Baylis-Hillman reaction and click reaction.  Further 
functionalization of these conjugates was achieved via reduction and succinylation.  The 
cytotoxicity evaluation of these compounds showed good potential as anti-cancer agents. 
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Chapter 1 
Introduction 
Betulin/Betulinic Acid 
   Betulin 1 and betulinic acid (B/BA) are pentacyclic lupane –type triterpenoids 
that are found as secondary metabolites in various types of plants distributed across of 
plant kingdom (Figure 1).1-2 Betulin is abundantly available in the outer part of the birch 
bark and these trees are native to northern America and various parts of Europe. 
Betulonic acid 2 and betulinic acid 3 can be easily synthesized from betulin via simple 
redox chemistry. Betulinic acid exhibits significant cytotoxicity against various cancer 
such as melanoma, gliblastoma pancreatic cancer, breast, and prostate cancer, etc.3 
Further their derivatives also exhibit diverse range of pharmacological properties ranging 
from anti-HIV, anti-micotic, anti-inflammatory, anti-parasitic, and antioxidants.4-13 There 
have been several reports on the synthesis and development of the betulin derivatives as 
potential medicinal agents.4-13 One of the recognized analogs of betulinic acid is 
bevirimat 4, which shows excellent anti-HIV activity with a new mechanism of action 
known as virus maturation inhibition. This molecule was developed by Panacos 
Pharmaceuticals and it reached Phase IIb clinical trials for the treatment of HIV. While 
the mechanism of action is unclear, several reports indicate that betulinic acid triggers 
apoptosis via direct regulation of mitochondrial pathways and increased production of 
caspase-3.4-14 Betulinic acid is also known to produce an anti-angiogenic response as well 
as affect the immuno-regulation in-vivo and arrest the cell cycle in the G2/M phase. 4-13 
 
  
2 
 Further, betulinic acid has been evaluated for the in vivo protective effect on 
dexamethasone-induced thymocyte apoptosis via reduction of oxidative stress.15 Betulin 
also inhibits TLR4/NF-kB pathway which results in reduction of kidney,16 liver, and 
lung17 injuries in rats. It also exhibits protective effects against colitis in mice.18 
 
 
Figure 1. Betulinic acid analogs. 
 
Multicomponent Reactions 
 Multi-component coupling reactions involve the combination of three or more 
precursors to form complex products. These reactions are highly atom, economical and 
exhibit excellent chemo selectivity. These reactions offer wide range of benefits in drug 
development as these are usually highly convergent one pot reactions which offer 
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3 
high diversity in the product formation. There have been several examples of the use of 
MCRs for the development of medicinal compounds such as kinase inhibitors, tubulin 
inhibitors, aspartyl protease inhibitors, serine protease inhibitors, metaloprotease 
inhibitors, GPCR inhibitors and so on.19 
 Some of the famous examples of MCRs include alkyne trimerization, Biginelli 
reaction, Bucherer-Bergs reaction, Gewald reaction, Greico three component coupling, 
Hantzsch pyridine synthesis, Mannich reaction, Passerini reaction, Pauson-Khand 
reaction, Petasis reaction, Ugi reaction, Strecker synthesis, etc.20 
 Passerini reaction involves the coupling of an isocyanide 7 with an aldehhyde 5 or 
ketone and a carboxylic acid 6 to yield an -acyloxy amide product 8;21 similarly the Ugi 
reaction involves four components coupling between an isocyanide 7, and 
aldehyde/ketone 5, an amine 9, and a carboxylic acid 6 to furnish -carboamido amides 
10 (Figure 2).22 
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Figure 2. Passerini and Ugi multicomponent coupling reactions. 
 Prior to the current work, our group has synthesized several betulinic acid analogs 
via multicomponent coupling reactions such as reductive amination, aldol condensation, 
and Passerini reaction.23 
Synthesis of Betulin-Chalcone Conjugates 
 The betulin-chalcone analog 15 was synthesized starting from betulin in five 
steps. Initially, betulin 1 was esterified as C3-C28 diester, which was then selectively 
hydrolyzed with aluminum isopropoxide to furnish the primary alcohol and subsequently 
oxidized with PCC to generate the aldehyde 11. Reaction of 11 with acetophenone 12 in 
the presence of potassium tert-butoxide in THF yielded the chalcone 13 with the 
concomitant hydrolysis of C3 ester.  This compound was further converted to the target 
compound succinic acid hemi ester 14 upon heating with succinic anhydride 14 in the 
presence of DMAP (Figure 3). 
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Figure 3. Preparation of betulin-chalcone conjugates. 
 
Synthesis of Betulin Conjugates via Passerini Reaction 
 The betulin aldehyde 11 was reacted with variety of carboxylic acids and 
isocyanides to furnish the C28 acetoxyamide derivatives 16 and 17. We were also able to 
synthesize a fluorescent BODIPY- betulin conjugate 19 via this protocol (Figure 4). 
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Figure 4. Preparation of betulin conjugates via Passerini reaction. 
 
Synthesis of Betulin Conjugates via Reductive Amination 
  The betulin aldehyde 20 was subjected to reductive amination with benzyl amine 
and sodium borohydride to yield secondary amine, which was then treated with benzyl 
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bromide to furnish the tertiary amine 21 (Figure 5).  
 
 
Figure 5. Preparation of betulin conjugates via reductive amination. 
 
Synthesis of Betulin Conjugates via Click Reaction 
 The click reaction is a 1,3-dipolar cycloaddition reaction involving the coupling 
of azides 22 and alkynes 23 in the presence of copper catalyst which results in the 
formation of 1,4 disubstituted 1,2,3 triazoles 24 (Figure 6).24 The product triazoles have 
wide range of medicinal application and are heavily used in natural product drug 
discovery,25 biopolymers,26 nano-technology,27-28 and other biomaterials.29 Click 
chemistry has been used extensively in high throughput synthesis and assembly of the 
chemical libraries.  
 
 
Figure 6. Click reaction. 
 Several betulin conjugates have been developed via click chemistry albeit 
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8 
with limited biological success. Bori et al. described an efficient strategy to link 
azidothymidine with betulin/betulinic acid via click chemistry. Selective monoproteciton 
of C28 primary alcohol in 1 with TBS chloride was achieved followed by the 
propargylation of C3 secondary alcohol to provide the ether 25a. Alternatively, betulin 
propargyl carbonate 25b was also obtained via the reaction of C28 silyl betulin ether with 
triphosgene followed by the addition of propargyl alcohol. Theses alkynes 25a-b were 
subjected to click coupling with azidothymidine to yield the triazoles 26a-b (Figure 7).30 
 
 
Figure 7. Betulin-AZT conjugates via click chemistry. 
 Bori and co-workers were also able to synthesize Betulinic acid-AZT conjugate 
29 via the succinylation of betulinic acid 3 with dimethylsuccinic anhydride 27 to yield 
the diacid 28. Esterification of C28 acid in 28 with propargyl bromide followed by click 
coupling with AZT resulted in the formation of the target compound 29 
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(Figure 8). Some of these compounds showed efficacy as anti-AIDS agents with EC50 
values ~0.1 M. 
 
 
Figure 8. Betulinic acid-AZT conjugates via click chemistry. 
 Similarly, Khan and co-workers synthesized N-aryl triazole conjugates 30 of 
betulinic acid 3 under identical conditions (Figure 9). Some of these analogs showed 
better potency against four human cancer cell lines (HL-60, MiaPaCa-2, PC-3, and A549) 
when compared to the parent natural products of betulinic acid. 31 
 Dang Thi et al reported betulinic acid AZT conjugates 32, which showed 
moderate cytotoxicity on KB and Hep-G2 cancer cells (Figure 10).32 
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Figure 9. Betulinic acid-triazole conjugates via click chemistry. 
 
 
Figure 10. Betulinic acid-AZT conjugates as anti-cancer agents. 
 Csuk et al reacted the aldehyde 33 with lithium acetylide followed by the 
oxidation of the resulting alcohol to furnish the diketone 34, which was then coupled with 
p-azidobenzoic acid or ethyl azidoacetate to yield the triazoles 35. Some of these 
molecules showed moderate cytotoxicity as established via fifteen human cancer cell line 
assay (Figure 11).33 
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Figure 11. Betulonic acid-triazole conjugates via click chemistry. 
 Shi et al synthesized the triazoles 37 via modification at the C30 position of 
betulin 1. Initial diesterification of betulin 1 followed by the selective monodeprotection 
of the primary alcohol and allylic bromination with NBS yielded the bromide 36. The 
bromide 36 was converted to azide and further subjected to click coupling with variety of 
terminal alkynes in a one-pot transformation to yield the target compounds 37. These 
compounds showed anticancer activity against Leukemia cell lines HL60 (Figure 12). 
Under similar condition the C30 triazoles 39 of betulinic acid 3 were also synthesized 
(Figure 13).34 
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Figure 12. Betulin-C30 triazole conjugates via click chemistry. 
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Figure 13. Betulinic acid-C30 triazole conjugates via click chemistry. 
 Chakrabarty et al converted the C3 alcohol of betulinic acid 3 as the chloroacetyl 
ester followed by the treatment with sodium azide to yield the azido acid 40 which was 
then subjected to click coupling with different alkynes to furnish the target compounds 41 
(Figure 14). The biological evaluation of these molecules showed anticancer activity in 
HT29 cell lines via induction of apoptosis and activation of caspase-3.35 
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Figure 14. Betulinic acid-C3 triazole ester conjugates via click chemistry. 
 Majeed and co-workers synthesized O-propargyl betulinic acid and coupled it 
with various azides using click chemistry resulting in the formation of triazolylbetulinic 
acid conjugates 42 (Figure 15). Some of these compounds showed potential as apoptotic 
agents.36 
 
 
Figure 15. Betulinic acid-C3 triazole ether conjugates via click chemistry. 
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Baylis-Hillman Reaction 
 Baylis-Hillman reaction was first reported in 1972 by German scientist A.B. 
Baylis and M.E.D. Hillman.37 This reaction is highly robust and involves in the coupling 
of activated alkenes with carbonyl or imine moieties resulting in the formation of densely 
functionalized allylic alcohols and amines.38  BH reaction involves the Michael addition 
of DABCO on an activated alkene followed by an aldol addition of the resulting enolate 
to the carbonyl compound. This reaction is quite versatile and has attracted the attention 
of several synthetic chemists worldwide. One of the minor drawbacks of this reaction 
deals with the slow rate of reaction. Accordingly, several approaches have been reported 
for the acceleration of the rate including the use of reactive activated 
olefins/electrophiles,39,40 microwave irradiation,41 enhanced hydrogen bonding 
capabilities,42 use of aqueous medium,43 and high pressures.44,45,46  Variety of activated 
olefins such as alkyl vinyl ketone,47,48,49 acrylates,50,51 acrylamides,41 acrylonitriles,47,52 
acrolein,53 vinyl sulfones,54 vinyl sulfoxides,55 vinyl phosphonates, and allenyl esters,56,57 
etc. have been used for the effective coupling with an array of aliphatic, alicyclic, 
aromatic, and heteroaromatic aldehydes and the corresponding allylic alcohols 46a-h 
have been obtained in high selectivity and yields (Figure 16).  Baylis-Hillman template 
offers another significant advantage because of the presence of multiple sites for further 
functionalization, which gains importance especially in medicinal chemistry in terms of 
the determination of structure activity relationship (SAR) profile. 
 
  
16 
 
Figure 16. Baylis-Hillman reaction. 
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Chapter 2 
Preparation of Betulin-Triazole Conjugates 
 In this project, we envisioned the preparation of betulinic acid-triazole conjugates 
using Baylis-Hillman reaction and click chemistry so as to improve the biological 
efficacy.  Herein, we provide an account of our synthetic and biological evaluation 
results.58 We started our synthesis with the preparation of the two precursors for click 
chemistry namely the azides and alkynes. We contemplated the synthesis of azides 
utilizing Baylis-Hillman reaction and the alkynes starting from betulinic acid. 
Synthesis of Azides via Baylis-Hillman Reaction  
 Under Baylis-Hillman reaction conditions, benzaldehyde 47 reacted with methyl 
acrylate 48 in the presence of DABCO at room temperature to afford the corresponding 
allylic alcohol 49 (Figure 17) as the colorless liquid in 78% yield. The three Baylis-
Hillman motif derived allylic azides 51a-c were then prepared from the alcohol 49. 
Nucleophilic substitution of allylic alcohol 49 with HBr in the presence of H2SO4 at 0°C 
yielded the corresponding allylic bromide 50 in 74% yield. Conversion of the allylic 
bromide to allylic azide 51a was achieved using sodium azide in acetone: H2O solvent 
medium at room temperature. The corresponding carboxylic acid derivative 52 was easily 
obtained upon hydrolysis in the presence of aq. NaOH in a mixture of THF/methanol 
solvent. Two other allylic azides 51b-c were synthesized by employing conventional 
amide coupling of the carboxylic acid 52 with N,N,N-trimethyl ethylenediamine 53 or N-
methyl piperazine 54 in the presence of 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoroborate (TBTU) as coupling agent and 
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diisopropylethylamine (DIPEA) as the base in dimethylformamide (DMF) as solvent 
(Figure 17). 
 
 
Figure 17. Preparation of -azidomethylcinnamamides. 
 After succeeding in the synthesis of three Baylis-Hillman derived allylic azides 
51a-c, we ventured into the synthesis of three β-azidoethylamides 51d-f.  The two β-
azidoethylamides 51d-e were prepared from BH allylic alcohol 49 (Figure 18). Reaction 
of 49 with acetic anhydride in the presence of triethylamine in dichloromethane (CH2Cl2) 
yielded corresponding acetate 55 in very good yield. The nucleophilic substitution (SN2ꞌ) 
of acetate 55 with N,N,Nꞌ-trimethylethylenediamine 53 in the presence of potassium 
carbonate (K2CO3) in DMF furnished the allylic amine 56 in 77% yield. Alkaline 
hydrolysis of 56 and the coupling of the resulting acid 57 with 2-azido ethylamine 
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in the presence of 1-ethyl-3-(-3-dimethylamino propyl) carbodimide hydrochloride 
(EDCI), 1-hydroxybenzotriazole (HOBt) and Hünig’s base yielded β-azidoethylamide 
51d in 74% yield.  The β-azidoethylamide 51e was obtained following a similar 
procedure by replacing N,N,N-trimethylethylendiamine 53 with N-methyl piperazine 54 
for coupling with acetate 55 followed by hydrolysis and amide coupling with 2-azido 
ethylamine (Figure 18).  
 The coupling of cinnamic acid 60 with 2-azidoethylamine under HOBt conditions 
furnished β-azidoethyl-cinnamamide 51f as a white solid in 73% yield (Figure 19). All of 
these compounds were characterized using proton, carbon, and mass spectral analysis. 
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Figure 18. Preparation of -aminomethyl N-azidoethylcinnamamides. 
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Figure 19. Preparation of N-azidoethylcinnamamide. 
 
Synthesis of N-Propargyl Betulonamide 
 Having prepared the azides from BH template, we focused our efforts on the 
functionalization of betulin for the preparation of click reaction counterpart. We initiated 
the synthesis of N-propargyl betulonamide 61 using Jones oxidation (CrO3 in acetone, 
conc. H2SO4) of betulin 1, resulting in the formation of betulonic acid 2 as a white solid. 
The coupling of betulonic acid 2 with propargyl amine using TBTU and Hünigs base 
furnished N-propargyl betulonamide 16 in 73% yield upon recrystallization from hexane 
(Figure 20).  
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Figure 20. Preparation of N-propargyl betulonamide. 
 
Synthesis of Betulinic Acid-Triazole Conjugates 
 After preparing the key intermediates N-propargyl betulonamide 61 and Baylis-
Hillman motif-derived azides 51a-f, we undertook the click coupling of these precursors 
for the synthesis of 1,2,3-triazoles (Figure 21).  
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Figure 21. Target betulinic acid-triazole conjugates. 
 
Click Coupling of N-Propargylbetulonamide with Azides 
  Initially, we attempted click coupling of methyl α-azidomethylcinnamate 51a 
with N-propargyl-betulonamide 61 using copper iodide.  Under these conditions, we were 
unable to obtain the product triazole 62a in decent yield even after performing the 
reaction in different solvents at room temperature or reflux conditions. Switching from 
copper iodide to copper sulfate and sodium ascorbate mediated cycloaddition in t-butyl 
alcohol/water resulted in the formation corresponding 1,2,3-triazole derivative 62a as a 
cream solid in 89% yield (Figure 22). The compound 62a was confirmed by the 
characteristic triazole proton signal δ 7.74 (1H, s) in 1H NMR spectrum as well as by 
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ESI-MS spectral peak at 709.55 (M+H)+. 
 
 
Figure 22. Coupling of N-propargylbetulonamide with azides. 
 After synthesizing the betulinic acid-triazole conjugate 62a, under identical 
conditions, the reaction of the remaining Baylis-Hillman motif derived azides 51b-f with 
N-propargyl betulonamide 61 furnished the corresponding triazoles 62b-f in high yield 
(Figures 22 and 23). All the compounds were well characterized using NMR and mass 
spectrometric analyses. 
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Figure 23. Triazoles obtained from N-propargylbetulonamide. 
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Reduction of Betulonamide-Triazole Conjugates 
 We then reduced the C3 ketone of 62a-f to the corresponding alcohol 63a-f using 
NaBH4 in methanol. Under these conditions, the betulinic acid-triazoles 63a-f were 
obtained in good yield (Figures 24 and 25). All the compounds were well characterized 
using NMR and mass spectrometric analyses. 
 
 
Figure 24. Reduction of betulonamide-triazole conjugates. 
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Figure 25. Triazoles obtained via reduction of betulonamide conjugates. 
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Succinylation of Betulinamide-Triazole Conjugates 
 Having prepared a series of C3 alcohol betulinic acid-triazoles 63a-f, in an effort 
towards increasing the hydrophilicity of these compounds, these alcohols were heated 
with succinic anhydride in toluene to yield the corresponding succinic acid hemiesters 
64a-f in 80-87% yield (Figures 26 and 27).  All the compounds were well characterized 
using NMR and mass spectrometric analyses. 
 
 
Figure 26. Succinylation of betulinamide-triazole conjugates. 
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Figure 27. Triazoles obtained via succinylation of betulinamide conjugates. 
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Biological Evaluation 
 All the synthetic analogs, as well as some of the intermediates, were evaluated for 
their cytotoxicity against murine breast cancer (4T1) and pancreatic cancer (MIA PaCa-
2) cell lines. The cells were purchased from ATCC, and the assays were performed using 
standard conditions by seeding the cells in 96 well plates, and the cell viability was 
determined using MTT assay. Primary screening was carried out at concentrations of 50 
M, 12.5 M and 1.5 M on two tumor cell lines as the parent natural product betulinic 
acid showed moderate activity (~60% inhibition of 4T1 and ~40% of MIAPaCa-2 cells) 
at 12.5 M, and majority of betulinic acid-triazole conjugates that were assayed, also 
displayed promising activity at this concentration (>90% inhibition of 4T1 and ~80-90% 
MIA PaCa-2 cells). The IC50 values were determined for the compounds that displayed 
moderate to good cytotoxicity. As shown in Table 1, the cytotoxicity profile of C3-
alcohol containing betulinic acid-triazoles 63a-f proved to be better relative to the C3-
ketone based analogs 62a-f. Interestingly, conversion of C3-alcohol to succinic acid hemi 
ester, i.e., compounds 64a-f, resulted in a slight reduction in anticancer activity. Two 
compounds (63d-e) in the C3-alcohol series displayed good anti-cancer activity against 
4T1 (2-3 μM) and MIA PaCa-2 (1-3 µM) cell lines when compared to their analogous 
C3-ketones 62d-e (4T1, 5-6 µM; MIA PaCa-2, 5-9 µM) and C3-hemi esters 64d-e (4T1, 
4-8 µM; MIA PaCa-2, 10-27 µM).  
 Based on these results, we perceive the significance of C3-alcohol unit and 
N,N,N’-trimethylethylenediamine/N-methylpiperazine motif at α-position of 
cinnamamides for improving the biological action of these molecules. It should also be 
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noted that none of the intermediates tested showed any toxicity, which leads us to believe 
that the BH motif is also required for the activity.  Efforts are currently underway to 
identify the mechanism of action for the lead derivatives as well as for the identification 
of potent candidate for further development. 
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Table 1 
In vitro cytotoxicity of betulinic acid-triazole conjugates. 
# Compound 4T1  [IC50 (µM)] MIA PaCa-2  [IC50 (µM)] 
1 62a NT NT 
2 62b 6.93 ± 1.09 9.87 ± 0.79 
3 62c 7.15 ± 0.18 14.99 ± 2.12 
4 62d 5.67 ± 0.10 8.11 ± 1.54 
5 62e 5.17 ± 0.60 5.98 ± 0.99 
6 62f NT NT 
7 63a 39.75 ± 9.45 NT 
8 63b 3.97 ± 0.73 2.44 ± 0.36 
9 63c 4.37 ± 0.43 8.69 ± 0.33 
10 63d 2.38 ± 0.45 1.36 ± 0.21 
11 63e 2.62 ± 0.24 1.64 ± 0.20 
12 63f 27.26 ± 12.2 32.50 ± 7.92 
13 64a 5.26 ± 0.65 47.58 ± 5.51 
14 64b 7.48 ± 0.59 21.73 ± 5.12 
15 64c 6.13 ± 0.81 14.44 ± 3.44 
16 64d 4.13 ± 0.22 9.66 ± 0.51 
17 64e 7.05 ± 0.53 24.28 ± 3.24 
18 64f 8.61 ± 2.27 NT 
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Table 1 (Continued) 
# Compound 4T1  [IC50 (µM)] MIA PaCa-2  [IC50 (µM)] 
19 3 (betulinic acid) 6.29 ± 0.96 25.63 ± 3.79 
 
 
NT = Not toxic 
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Conclusions 
 In conclusion, we have prepared betulinic acid-triazole derivatives utilizing 
Baylis-Hillman reaction and click chemistry as the key protocols in our synthesis. These 
compounds were tested for their biological efficacy against murine breast cancer cell line 
(4T1) and human pancreatic cancer cell line (MIA PaCa-2).  Based on these in vitro 
assays, we have been able to identify two series of betulin derivatives for further SAR 
and pre-clinical studies.  The ready availability of betulin from natural resources as well 
as the great chemical diversity afforded by the Baylis-Hillman template imparts 
significance to this class of compounds for potential development as anti-cancer agents. 
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Chapter 3 
Experimental Procedures 
Materials and Methods 
 All the reactants were of reagent grade, purchased from Acros Organics, Alfa 
Aesar or Sigma Aldrich, and used without further purification. All solvents were used 
without further drying or purification and were of ACS grade purchased from Fisher 
Scientific.  All operations were carried out under an inert atmosphere of nitrogen. 
Glassware for all reactions was oven dried at 125 °C and cooled under nitrogen prior to 
use. Liquid reagents and solvents were introduced by oven-dried syringes or cannulas 
through septa sealed flasks under a nitrogen atmosphere. 
Instrumentation 
 Nuclear Magnetic Spectroscopy (NMR) spectra were produced using a Varian 
400 MHz spectrophotometer. The instrument was maintained at 25o C operating at 400 
MHz for 1H NMR, and 101 MHz for 13C NMR. The deuterated solvent (CDCl3, DMSO-
d6) used for each respective spectrum is referenced to the appropriate literature peak shift. 
Procedures 
General amide-coupling procedure A. To a stirred solution of the appropriate 
acid (1.0 mmol) in dimethylformamide (10.0 mL), was added N,N-diisopropylethylamine 
(2.0 mmol) followed by TBTU (1.1 mmol) at 0 °C and stirred for 30 min. The 
appropriate amine (1.0 mmol) was then added in one portion and stirred overnight at 
room temperature. Upon completion (as indicated by TLC), the reaction mixture was 
quenched by the addition of saturated NaHCO3 and extracted with dichloromethane (2 x 
10.0 mL). The combined extracts were washed with cold water (10.0 mL) and brine (10.0 
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mL). The organic layer was dried over anhydrous Na2SO4, concentrated in vacuo, and 
purified by column chromatography (silica gel, hexanes:ethyl acetate) to obtain pure 
amides.   
General amide-coupling procedure B. N,N-diisopropylethylamine (2.0 mmol), 
HOBt (1.1 mmol), and EDCI (1.1 mmol) were added at 0 °C to a stirred solution of the 
appropriate acid (1.0 mmol) in dichloromethane (10.0 mL) and the reaction was stirred 
for 30 min. The appropriate amine (1.0 mmol) was added in one portion and the reaction 
was stirred overnight at room temperature. After completion of the reaction as indicated 
by TLC, the reaction mixture was quenched by the addition of saturated NaHCO3 
solution and worked up with dichloromethane (2 x 10.0 mL). The combined extracts 
were washed with brine (10.0 mL), dried over anhydrous Na2SO4, concentrated in vacuo, 
and purified by column chromatography (silica gel, hexanes:ethyl acetate) to obtain pure 
amides in good yields.  
 
 
 (E)-2-(azidomethyl)-N-(2-(dimethylamino)ethyl)-N-methyl-3-phenylacrylamide:  The 
reaction of (E)-2-(azidomethyl)-3-phenylacrylic acid (1.0 g, 4.9 mmol) with N,N,N’-
trimethylethylenediamine (602 mg, 5.9 mmol) as per the general amide coupling 
procedure A yielded 1.02 g (72%) of 51b as a pale brown liquid.  1H NMR (400 MHz, 
CDCl3): δ (ppm) 7.31 – 7.44 (m, 3H), 7.26 – 7.31 (m, 2H), 6.78 (s, 1H), 4.30 (s, 2H), 
3.61 (t, J = 7.1 Hz, 2H), 3.15 (s, 3H), 2.55 (t, J = 7.1 Hz, 2H), 2.28 (s, 6H); 13C NMR 
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(101 MHz, CDCl3): δ (ppm) 169.5 134.4, 133.5, 131.6, 128.8, 128.6, 128.4, 49.4, 45.7. 
ESIMS: m/z calculated for C15H21N5O (M+H)
+ 288.18, found 288.38. 
 
 
(E)-2-(azidomethyl)-1-(4-methylpiperazin-1-yl)-3-phenylprop-2-en-1-one: The reaction 
of (E)-2-(azidomethyl)-3-phenylacrylic acid (1.0 g, 4.92 mmol) with N-methylpiperazine 
(590 mg, 5.90 mmol) as per the general amide coupling procedure A furnished 1.04 g 
(74%) of 51c as a pale brown liquid. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.24 – 7.41 
(m, 5H), 6.69 (s, 1H), 4.26 (s, 2H), 3.61 – 3.80 (m, 4H), 2.37 – 2.50 (m, 4H), 2.29 (s, 
3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 169.9, 134.3, 134.0, 131.2, 129.0, 128.9, 
128.8, 55.0, 49.5, 46.2. ESIMS: m/z calculated for C15H19N5O (M+H)
+ 286.16, found 
286.30. 
 
 
Methyl (E)-2-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-3-phenylacrylate: 
N,N,N’-Trimethylethylenediamine (521 mg, 5.1 mmol) and K2CO3 (883 mg, 6.40 mmol) 
were added to a stirred solution of 55 (1.0 g, 4.27 mmol ) in N,N-dimethylformamide 
(10.0 mL) at room temperature and the reaction mixture was stirred overnight. Upon 
completion (TLC), the reaction was quenched with cold water and extracted with ethyl 
acetate (2 x 20.0 mL). The combined organic layers were washed thoroughly 
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with cold water (2 x 10.0 mL), brine (2 x 10.0 mL) and dried over anhydrous Na2SO4.  
The ethyl acetate was concentrated in vacuo and purified by column chromatography 
(silica gel, hexanes: ethyl acetate, 1:4) to obtain 56 as brown liquid (912 mg, 77%). 1H 
NMR (400 MHz, CDCl3): δ (ppm) 7.80 (s, 1H), 7.57 – 7.61 (m, 2H), 7.29 – 7.41 (m, 3H), 
3.82 (s, 3H), 3.39 (s, 2H), 2.48 – 2.54 (m, 2H), 2.37 – 2.44 (m, 2H), 2.21 (s, 6H), 2.18 (s, 
3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 168.9, 142.6, 135.3, 130.4, 130.2, 128.7, 
128.3, 57.2, 55.5, 53.1, 51.9, 45.8, 41.9. ESIMS: m/z calculated for C16H24N2O2 (M+H)
+ 
277.19, found 277.38. 
 
 
(E)-2-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-3-phenylacrylic acid: aq. NaOH 
(2.9 mL, 2.5 M, 7.3 mmol) was added to a solution of 56 (1.0 g, 3.6 mmol) in 
THF:MeOH (9:1, 20.0 mL) at 0 °C and the reaction was stirred overnight at room 
temperature. Upon completion (TLC), the solution was acidified to pH 6 with 1N HCl.  
The solution was concentrated in vacuo and the resulting slurry was dissolved in 
isopropyl alcohol to effect the precipitation of sodium chloride. The reaction was then 
filtered and the filtrate was concentrated in vacuo to yield 671 mg (71%) of 57 as pale 
cream-colored semi-solid.  1H NMR (400 MHz, CDCl3): δ (ppm) 7.96 (s, 1H), 7.33 – 
7.42 (m, 3H), 7.26 – 7.31 (m, 2H), 3.81 (s, 2H), 3.45 (m, 2H), 3.19 (m, 2H), 2.89 (s, 6H), 
2.43 (s, 3H); 13C NMR (101 MHz, DMSO-d6): δ (ppm) 169.5, 142.9, 134.9, 130.4, 129.5, 
129.1, 52.9, 52.7, 51.3, 42.6, 41.4. ESIMS: m/z calculated for C15H22N2O2 (M+H)
+ 
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263.17, found 263.37.  
 
 
(E)-N-(2-azidoethyl)-2-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-3-
phenylacrylamide 7c: The reaction of 57 (500 mg, 1.90 mmol) with 2-azidoethylamine 
(180 mg, 2.09 mmol) as per the general amide-coupling procedure B yielded 460 mg 
(74%) of 51d as a pale orange liquid.  1H NMR (400 MHz, CDCl3): δ (ppm) 10.10 (s, 
1H), 7.96 (s, 1H), 7.21 – 7.41 (m, 5H), 3.49 – 3.53 (m, 4H), 3.39 (s, 2H), 2.43 – 2.51 (m, 
2H), 2.34 – 2.42 (m, 2H), 2.24 (s, 6H), 2.14 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 
(ppm) 168.6, 140.1, 136.1, 131.0, 129.2, 128.4, 128.0, 56.8, 54.6, 53.1, 50.8, 45.6, 42.0, 
39.7. ESIMS: m/z calculated for C17H26N6O (M+H)
+ 331.22, found 331.35. 
 
 
Methyl (E)-2-((4-methylpiperazin-1-yl)methyl)-3-phenylacrylate: The reaction of 55 (1.0 
g, 4.3 mmol) with N-methylpiperazine (512 mg, 5.1 mmol) and K2CO3 (883 mg, 6.4 
mmol) provided 943 mg (81%) of 58 as a pale cream liquid. 1H NMR (400 MHz, 
CDCl3): δ (ppm) 7.84 (s, 1H), 7.63 – 7.68 (m, 2H), 7.32 – 7.41 (m, 3H), 3.81 (s, 3H), 
3.35 (s, 2H), 2.31 – 2.63 (m, 8H), 2.26 (s, 3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 
169.3, 143.6, 135.6, 130.7, 129.9, 129.1, 128.6, 55.5, 53.4, 52.8, 52.3, 46.3. ESIMS: m/z 
  
40 
calculated for C16H22N2O2 (M+H)
+ 275.17, found 275.10. 
 
 
(E)-2-((4-methylpiperazin-1-yl)methyl)-3-phenylacrylic acid: The reaction of 58 (1.0 g, 
3.6 mmol) and aq. NaOH (2.9 mL, 2.5 M, 7.3 mmol) yielded 710 mg (74%) of 59 as a 
pale cream-colored solid.  1H NMR (400 MHz, CDCl3): δ (ppm) 8.02 (s, 1H), 7.38 – 7.42 
(m, 3H), 7.30 – 7.32 (m, 2H), 3.66 (s, 2H), 2.95 – 3.10 (m, 8H), 2.69 (s, 3H). 13C NMR 
(101 MHz, CDCl3): δ (ppm) 169.5, 142.9, 134.6, 129.5, 128.8, 128.3, 127.9, 53.2, 52.9, 
49.4, 43.4. ESIMS: m/z calculated for C15H20N2O2 (M
+) 260.15, found 260.80. 
 
 
(E)-N-(2-azidoethyl)-2-((4-methylpiperazin-1-yl)methyl)-3-phenylacrylamide: The 
reaction of 59 (250 mg, 0.96 mmol) with 2-azidoethylamine (90 mg, 1.05 mmol) as per 
the general amide-coupling procedure B yielded 226 mg, (72%) of 51e as a pale orange 
liquid. 1H NMR (400 MHz, CDCl3): δ (ppm) 10.04 (s, 1H), 7.92 (s, 1H), 7.18 – 7.36 (m, 
5H), 3.50 – 3.56 (m, 2H), 3.45 – 3.49 (m, 2H), 3.39 (s, 2H), 2.33 – 2.68 (m, 8H), 2.25 (s, 
3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 168.6, 140.7, 135.7, 129.8, 129.2, 128.5, 
128.2, 55.3, 54.9, 52.5, 51.2, 46.2, 38.9. ESIMS: m/z calculated for C17H24N6O (M+H)
+ 
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329.20, found 329.33. 
 
 
 
 Preparation of triazole 62a. To a stirred solution of alkyne 61 (450 mg, 0.9 
mmol) and azide 51a (198 mg, 0.9 mmol) in a mixture of t-butanol/water (1:1, 8.0 mL), 
was added CuSO4 (23 mg, 0.1 mmol) and sodium ascorbate (36 mg, 0.2 mmol). The 
reaction mixture was stirred overnight at room temperature. Upon completion (TLC), the 
reaction was concentrated in vacuo and diluted with water to effect precipitation. The 
resulting solid was filtered, washed with water, and further purified via column 
chromatography (silica gel, methanol:dichloromethane, 2:3) to obtain 528 mg (89%) of 
1,2,3-triazole 62a as a white solid.  Mp 124 – 126 °C, 1H NMR (400 MHz, CDCl3): δ 
(ppm) 8.07 (s, 1H), 7.74 (s, 1H), 7.62 (d, J = 7.4 Hz, 2H), 7.39 – 7.46 (m, 3H), 6.36 (t, J 
= 5.2 Hz, 1H), 5.35 (s, 2H), 4.72 (s, 1H), 4.58 (s, 1H), 4.40 – 4.56 (m, 2H), 3.84 (s, 3H), 
3.11 (dt, J = 4.2, 11.0 Hz, 1H), 2.33 – 2.49 (m, 3H), 0.70 – 2.04 (m, 21H), 1.66 (s, 3H), 
1.03 (s, 3H), 0.95 (s, 3H), 0.93 (s, 3H), 0.83 (s, 3H), 0.75 (s, 3H); 13C NMR (101 MHz, 
CDCl3): δ (ppm) 218.4, 176.5, 167.2, 151.1, 146.2, 145.2, 133.7, 130.2, 129.9, 129.2, 
125.1, 123.4, 109.6, 55.8, 55.1, 52.8, 50.2, 50.1, 47.5, 47.1, 46.9, 42.6, 40.8, 39.8, 38.4, 
37.9, 37.0, 34.8, 34.3, 33.7, 33.6, 31.0, 29.5, 26.8, 25.8, 21.6, 21.2, 19.8, 19.7, 16.1, 15.8, 
14.7; ESIMS: m/z calculated for C44H60N4O4 (M+H)
+ 709.47, found 709.55. 
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Preparation of triazole 62b: Procedure similar to that of 62a. This compound was 
prepared by the reaction of alkyne 61 with azide 51b. Yield: 88%; cream color solid; mp 
98 – 101 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.62 (s, 1H), 7.33 – 7.46 (m, 5H), 
6.92 (s, 1H), 6.25 (t, J = 5.3 Hz, 1H), 5.31 – 5.42 (m, 2H), 4.73 (s, 1H), 4.55 – 4.61 (m, 
1H), 4.50 (dd, J = 5.5, 15.0 Hz, 1H), 4.44 (dd, J = 5.5, 15.2 Hz, 1H), 3.42 – 3.50 (m, 2H), 
3.12 (dt, J = 4.3, 11.2 Hz, 1H), 3.00 (brs, 3H), 2.33 – 2.52 (m, 5H), 2.24 (brs, 6H), 0.78 – 
2.01 (m, 21H), 1.67 (s, 3H), 1.05 (s, 3H), 0.99 (s, 3H), 0.94 (s, 3H), 0.87 (s, 3H), 0.82 (s, 
3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 218.0, 176.2, 150.8, 145.0, 134.8, 134.0, 
130.2, 128.8 (2C), 128.7, 123.2, 109.4, 55.5, 54.9, 50.0, 49.9, 48.5, 47.2, 46.6, 45.6, 42.4, 
40.6, 39.6, 38.2, 37.7, 36.8, 34.7, 34.1, 33.6, 33.4, 30.8, 29.6, 29.3, 26.6, 25.6, 21.4, 20.9, 
19.6, 19.4, 15.9, 15.6, 14.5; ESIMS: m/z 779.70 [100%, (M+H)+], HRMS-ESI: calculated 
for C48H70N6O3 [M+H]
+ 779.5582, found 779.5578. 
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Preparation of triazole 62c: Procedure similar to that of 62a. This compound was 
prepared by the reaction of alkyne 61 with azide 51c. Yield: 90%; cream color solid; mp 
134 – 137 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.61 (s, 1H), 7.34 – 7.43 (m, 5H), 
6.87 (s, 1H), 6.25 (m, 1H), 5.35 (s, 2H), 4.73 (s, 1H), 4.59 (s, 1H), 4.52 (dd, J = 4.0, 16.0 
Hz, 1H), 4.42 (dd, J = 4.0, 16.0 Hz, 1H), 3.63 (m, 4H), 3.12 (dt, J = 4.3, 11.2 Hz, 1H), 
2.34 – 2.52 (m, 3H), 2.17 – 2.30 (m, 4H), 2.25 (s, 3H), 0.77 – 1.94 (m, 21H), 1.67 (s, 
3H), 1.05 (s, 3H), 1.01 (s, 3H), 0.94 (s, 3H), 0.87 (s, 3H), 0.81 (s, 3H); 13C NMR (101 
MHz, CDCl3): δ (ppm) 218.4, 176.5, 169.0, 150.9, 145.3, 134.8, 134.1, 129.9, 129.1, 
129.0, 128.9, 123.7, 109.6, 55.8, 55.2, 54.9, 50.3, 50.1, 48.8, 47.5, 46.9, 46.2, 42.7, 40.9, 
39.8, 38.4, 37.9, 37.1, 34.9, 34.3, 33.8, 33.7, 31.0, 29.6, 26.8, 25.8, 21.6, 21.2, 19.8, 19.7, 
16.2, 15.8, 14.8; ESIMS: m/z 777.65 [100%, (M+H)+], HRMS-ESI: calculated for 
C48H68N6O3 [M+Na]
+ 799.5245, found 799.5239. 
 
 
Preparation of triazole 62d: Procedure similar to that of 62a. This compound was 
  
44 
prepared by the reaction of alkyne 61 with azide 51d. Yield: 85%; cream color solid; mp 
108 – 110 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 9.89 (brs, 1H), 7.94 (s, 1H), 7.59 (s, 
1H), 7.22 – 7.40 (m, 5H), 6.37 (brs, 1H), 4.73 (s, 1H), 4.56 – 4.60 (m, 3H), 4.51 (dd, J = 
5.4, 15.0 Hz, 1H), 4.44 (dd, J = 5.5, 15.0 Hz, 1H), 3.65 – 3.82 (m, 2H), 3.34 (s, 2H), 3.12 
(dt, J = 4.2, 11.1 Hz, 1H), 2.34 – 2.52 (m, 7H), 2.19 (brs, 3H), 2.07 (s, 6H), 0.82 – 1.97 
(m, 21H), 1.67 (s, 3H), 1.05 (s, 3H), 1.01 (s, 3H), 0.94 (s, 3H), 0.90 (s, 3H), 0.84 (s, 3H); 
13C NMR (101 MHz, CDCl3): δ (ppm) 218.1, 176.4, 168.5, 150.8, 145.0, 140.1, 135.6, 
130.5, 128.9, 128.3, 127.9, 122.9, 109.4, 55.9, 55.5, 54.9, 53.8, 52.7, 50.0, 49.9, 49.2, 
47.3, 46.7, 44.9, 42.4, 41.6, 40.6, 39.9, 39.6, 38.2, 37.7, 36.9, 34.7, 34.1, 33.6, 33.4, 30.8, 
29.6, 29.3, 26.6, 25.6, 21.4, 21.0, 19.7, 19.4, 15.9, 15.6, 14.5; ESIMS: m/z 822.65 [100%, 
(M+H)+], HRMS-ESI: calculated for C50H75N7O3 [M+Na]
+ 844.5824, found 844.5831. 
 
 
Preparation of triazole 62e: Procedure similar to that of 62a. This compound was 
prepared by the reaction of alkyne 61 with azide 51e. Yield: 87%; cream color solid; mp 
118 – 120 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 9.87 (s, 1H), 7.92 (s, 1H), 7.61 (s, 
1H), 7.22 – 7.37 (m, 3H), 7.20 – 7.25 (m, 2H), 6.23 – 6.29 (m, 1H), 4.73 (s, 1H), 4.59 (s, 
1H), 4.38 – 4.55 (m, 4H), 3.79 – 3.92 (m, 2H), 3.34 (s, 2H), 3.08 – 3.15 (m, 1H), 2.29 – 
2.52 (m, 11H), 2.25 (s, 3H), 0.76 – 1.92 (m, 21H), 1.75 (s, 3H), 1.04 (s, 3H), 1.00 (s, 3H), 
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0.94 (s, 3H), 0.90 (s, 3H), 0.81 (s, 3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 218.3, 
176.7, 168.9, 150.9, 145.5, 140.9, 135.4, 129.5, 129.2, 128.5, 128.3, 123.2, 109.7, 55.7, 
55.2, 54.9, 54.9, 52.3, 50.2, 50.1, 49.9, 47.5, 46.9, 45.9, 42.7, 40.9, 39.8, 39.4, 38.4, 38.0, 
37.1, 35.0, 34.3, 33.8, 33.7, 31.0, 29.6, 26.8, 25.8, 21.6, 21.2, 19.8, 19.7, 16.2, 15.8, 14.8; 
ESIMS: m/z 820.70 [100%, (M+H)+], HRMS-ESI: calculated for C50H73N7O3 [M+H]
+ 
820.5848, found 820.5877. 
 
 
Preparation of triazole 62f: Procedure similar to that of 62a. This compound was 
prepared by the reaction of alkyne 61 with azide 51f. Yield: 91%; white solid; mp 139 – 
141 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.62 (d, J = 15.6 Hz, 1H), 7.60 (s, 1H), 
7.46 – 7.51 (m, 2H), 7.32 – 7.36 (m, 3H), 6.26 – 6.42 (m, 3H), 4.70 (s, 1H), 4.57 (s, 1H), 
4.46 – 4.54 (m, 3H), 4.40 (dd, J = 5.7, 15.0 Hz, 1H), 3.85 – 3.94 (m, 2H), 3.12 (dt, J = 
4.4, 11.1 Hz, 1H), 2.32 – 2.51 (m, 3H), 0.75 – 1.95 (m, 21H), 1.64 (s, 3H), 1.02 (s, 3H), 
0.98 (s, 3H), 0.92 (s, 3H), 0.88 (s, 3H), 0.80 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 
(ppm) 218.5, 176.9, 166.7, 150.8, 145.7, 141.7, 134.8, 130.1, 129.0, 128.0, 123.6, 120.3, 
109.8, 55.8, 55.1, 50.2, 50.1, 49.9, 47.5, 46.9, 42.7, 40.8, 39.8, 38.4, 37.9, 37.1, 35.0, 
34.4, 33.8, 33.6, 31.0, 29.6, 26.8, 25.8, 21.6, 21.2, 19.8, 19.6, 16.2, 15.9, 14.7; ESIMS: 
m/z 708.55 [100%, (M+H)+], HRMS-ESI: calculated for C44H61N5O3 [M+H]
+ 708.4847, 
found 708.4833. 
  
46 
 
 
 Preparation of alcohol 63a. To a stirred solution of the appropriate ketone 62a 
(180 mg, 0.2 mmol) in methanol at 0 °C, was added NaBH4 (14 g, 0.4 mmol), and stirred 
for 2 h at room temperature. Upon completion of reaction (as monitored by TLC), the 
reaction mixture was concentrated in vacuo, diluted with water and extracted with ethyl 
acetate (2 x 10.0 mL). The combined organic extracts were washed with brine (10.0 mL), 
dried over anhydrous Na2SO4, concentrated under vacuum and purified via column 
chromatography (silica gel, hexane:ethyl acetate, 1:2) to obtain 155 mg (86%) of pure 
alcohol 63a as a white solid. Mp 123 – 125 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 
8.06 (s, 1H), 7.72 (s, 1H), 7.57 – 7.64 (m, 2H), 7.39 – 7.46 (m, 3H), 6.49 (m, 1H), 5.33 
(s, 2H), 4.70 (s, 1H), 4.56 (s, 1H), 4.50 (dd, J = 5.7, 15.0 Hz, 1H), 4.41 (dd, J = 5.5, 15.0 
Hz, 1H), 3.82 (s, 3H), 3.03 – 3.22 (m, 2H), 2.34 (dt, J = 3.5, 12.7 Hz, 1H), 0.59 – 2.02 
(m, 24H), 1.64 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H), 0.72 (s, 3H), 0.70 (s, 3H), 0.69 (s, 3H); 
13C NMR (101 MHz, CDCl3): δ (ppm) 176.5, 167.2, 151.2, 146.2, 145.2, 133.8, 130.2, 
129.9, 129.2, 125.1, 123.3, 109.6, 79.1, 55.8, 55.5, 52.8, 50.8, 50.3, 47.1, 47.0, 42.6, 40.9, 
39.0, 38.9, 38.4, 37.9, 37.4, 34.8, 34.5, 33.7, 31.1, 29.6, 28.2, 27.6, 25.8, 21.1, 19.7, 18.5, 
16.3, 16.0, 15.6, 14.8; ESIMS: m/z calculated for C44H62N4O4 (M+H)
+ 711.48, found 
711.70. 
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Preparation of 63b: Procedure similar to that of 63a. Yield: 85%; cream color solid; mp 
118 – 121 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.60 (s, 1H), 7.33 – 7.43 (m, 5H), 
6.99 (s, 1H), 6.25 – 6.34 (m, 1H), 5.35 (s, 2H), 4.72 (s, 1H), 4.58 (s, 1H), 4.49 (dd, J = 
5.6, 15.1 Hz, 1H), 4.42 (dd, J = 5.6, 15.1 Hz, 1H), 3.61 (brs, 2H), 3.05 – 3.18 (m, 5H), 
2.29 – 2.77 (m, 10H), 0.63 – 1.94 (m, 23H), 1.66 (s, 3H), 0.94 (s, 3H), 0.93 (s, 3H), 0.77 
(s, 3H), 0.76 (s, 3H), 0.73 (s, 3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 176.4, 150.8, 
135.1, 133.9, 129.8, 128.84, 128.80, 128.78, 123.3, 109.4, 78.9, 55.6, 55.3, 50.5, 50.1, 
48.6, 46.8, 44.9, 44.8, 42.4, 40.7, 38.8, 38.7, 38.2, 37.7, 37.1, 34.8, 34.3, 33.5, 30.8, 29.4, 
27.9, 27.4, 25.6, 20.9, 19.4, 18.3, 16.1, 15.8, 15.4, 14.6; ESIMS: m/z 781.70 [100%, 
(M+H)+], HRMS-ESI: calculated for C48H72N6O3 [M+Na]
+ 803.5558, found 803.5558. 
 
 
Preparation of 63c: Procedure similar to that of 63a. Yield: 88%; white solid; mp 134 – 
136 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.60 (s, 1H), 7.34 – 7.42 (m, 5H), 
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6.86 (s, 1H), 6.24 (t, J = 5.6 Hz, 1H), 5.34 (s, 2H), 4.73 (s, 1H), 4.58 (s, 1H), 4.52 (dd, J 
= 5.6, 15.1 Hz, 1H), 4.42 (dd, J = 5.6, 15.1 Hz, 1H), 3.66 (m, 4H), 3.06 – 3.19 (m, 2H), 
2.17 – 2.35 (m, 5H), 2.26 (s, 3H), 0.63 – 1.93 (m, 24H), 1.67 (s, 3H), 0.94 (s, 3H), 0.93 
(s, 3H), 0.76 (s, 6H), 0.73 (s, 3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 176.3, 168.8, 
150.8, 145.1, 134.6, 133.8, 129.6, 128.8, 128.8, 128.7, 123.5, 109.3, 78.8, 55.7, 55.3, 
54.7, 50.5, 50.1, 48.5, 46.7, 45.8, 42.4, 40.7, 38.8, 38.7, 38.2, 37.7, 37.1, 34.7, 34.3, 33.5, 
30.8, 29.4, 27.9, 27.4, 25.6, 20.9, 19.5, 18.3, 16.1, 15.8, 15.4, 14.6; ESIMS: m/z 779.70 
[100%, (M+H)+], HRMS-ESI: calculated for C48H70N6O3 [M+Na]
+ 801.5402, found 
801.5443. 
 
 
Preparation of 63d: Procedure similar to that of 63a. Yield: 90%; cream color solid; mp 
119 – 122 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 9.95 (s, 1H), 7.96 (s, 1H), 7.58 (s, 
1H), 7.24 – 7.41 (m, 5H), 6.33 (s, 1H), 4.72 (s, 1H), 4.55 – 4.64 (m, 3H), 4.51 (dd, J = 
5.5, 15.0 Hz, 1H), 4.43 (dd, J = 5.5, 15.0 Hz, 1H), 3.69 – 3.83 (m, 2H), 3.33 (s, 2H), 3.06 
– 3.20 (m, 2H), 2.29 – 2.42 (m, 4H), 2.07 (brs, 3H), 2.07 (s, 6H), 0.63 – 1.95 (m, 25H), 
1.67 (s, 3H), 0.94 (s, 3H), 0.93 (s, 3H), 0.80 (s, 3H), 0.79 (s, 3H), 0.74 (s, 3H); 13C NMR 
(101 MHz, CDCl3): δ (ppm) 176.4, 168.5, 150.8, 144.9, 140.1, 135.6, 130.5, 129.0, 
128.2, 127.9, 122.9, 109.4, 78.9, 56.1, 55.6, 55.3, 54.0, 52.5, 50.6, 50.1, 49.2, 46.8, 45.0, 
42.4, 41.7, 40.7, 39.9, 38.8, 38.7, 38.2, 37.7, 37.2, 34.7, 34.3, 33.5, 30.9, 29.4, 
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27.9, 27.4, 25.6, 20.9, 19.4, 18.2, 16.1, 15.8, 15.4, 14.6; ESIMS: m/z 824.75 [100%, 
(M+H)+], HRMS-ESI: calculated for C50H77N7O3 [M+Na]
+ 846.5980, found 846.5983. 
 
 
Preparation of 63e: Procedure similar to that of 63a. Yield: 89%; cream color solid; mp 
130 – 132 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 9.86 (t, J = 4.0 Hz, 1H), 7.92 (s, 
1H), 7.58 (s, 1H), 7.20 – 7.39 (m, 5H), 6.26 (t, J = 5.7 Hz, 1H), 4.73 (s, 1H), 4.58 (s, 1H), 
4.46 – 4.56 (m, 3H), 4.40 (dd, J = 5.6, 15.0 Hz, 1H), 3.79 – 3.91 (m, 2H), 3.34 (s, 2H), 
3.08 – 3.18 (m, 2H), 2.21 – 2.48 (m, 10H), 2.25 (s, 3H), 0.64 – 1.92 (m, 25H), 1.67 (s, 
3H), 0.94 (s, 3H), 0.93 (s, 3H), 0.80 (s, 3H), 0.76 (s, 3H), 0.74 (s, 3H); 13C NMR (101 
MHz, CDCl3): δ (ppm) 176.5, 168.7, 150.8, 145.3, 140.8, 135.2, 129.3, 128.9, 128.3, 
128.0, 123.1, 109.4, 78.8, 55.6, 55.3, 54.8, 54.6, 52.1, 50.5, 50.1, 49.7, 46.8, 45.7, 42.4, 
40.7, 39.2, 38.8, 38.7, 38.2, 37.8, 37.2, 34.7, 34.3, 33.5, 30.8, 29.4, 27.9, 27.4, 25.6, 20.9, 
19.4, 18.2, 16.2, 15.8, 15.4, 14.6; ESIMS: m/z 822.70 [100%, (M+H)+], HRMS-ESI: 
calculated for C50H75N7O3 [M+Na]
+ 844.5824, found 844.5852. 
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Preparation of 63f: Procedure similar to that of 63a. Yield: 90%; gray color solid; mp 185 
– 187 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.63 (d, J = 15.6 Hz, 1H), 7.60 (s, 1H), 
7.45 – 7.53 (m, 2H), 7.33 – 7.60 (m, 3H), 6.38 (d, J = 15.6 Hz, 1H), 6.24 – 6.35 (m, 2H), 
4.71 (s, 1H), 4.57 (s, 1H), 4.38 – 4.54 (m, 4H), 3.86 – 3.93 (m, 2H), 3.06 – 3.17 (m, 2H), 
2.26 – 2.39 (m, 1H), 0.62 – 1.94 (m, 24H), 1.65 (s, 3H), 0.92 (s, 6H), 0.78 (s, 3H), 0.75 
(s, 3H), 0.73 (s, 3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 176.7, 166.4, 150.7, 145.5, 
141.6, 134.6, 129.8, 128.8, 127.8, 123.4, 120.0, 109.4, 78.9, 55.6, 55.3, 50.5, 50.1, 49.7, 
46.7, 42.4, 40.7, 39.5, 38.8, 38.7, 38.2, 37.8, 37.1, 34.7, 34.3, 33.4, 30.8, 29.4, 27.9, 27.4, 
25.6, 20.9, 19.4, 18.2, 16.1, 15.8, 15.4, 14.6; ESIMS: m/z calculated for C44H63N5O3 
(M+H)+ 710.50, found 710.65. 
 
 
  
 Preparation of succinic acid hemiester 64a. A stirred solution of alcohol 63a 
(110 mg, 0.1 mmol), DMAP (19 mg, 0.1 mmol), and succinic anhydride (31 mg, 0.3 
mmol) in toluene (4.0 mL) was refluxed overnight. Upon completion (TLC), the 
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reaction mixture was concentrated in vacuo, diluted with water, and extracted with ethyl 
acetate (2 x 10.0 mL). The combined extracts were washed with brine (10.0 mL), dried 
over anhydrous Na2SO4, concentrated under reduced pressure, and purified using column 
chromatography (silica gel, hexanes:ethyl acetate, 1:3) to obtain 109 mg (87%) of pure 
succinic acid hemi ester 64a as a white solid.  Mp 122 – 125 °C; 1H NMR (400 MHz, 
CDCl3): δ (ppm) 8.07 (s, 1H), 7.73 (s, 1H), 7.58 – 7.63 (m, 2H), 7.41 – 7.47 (m, 3H), 
6.71 (t, J = 5.9 Hz, 1H), 5.34 (s, 2H), 4.71 (s, 1H), 4.57 (s, 1H), 4.43 – 4.50 (m, 3H), 3.84 
(s, 3H), 3.10 (dt, J = 4.3, 11.1 Hz, 1H), 2.57 – 2.69 (m, 4H), 2.32 (dt, J = 3.6, 12.3 Hz, 
1H), 0.65 – 1.98 (m, 23H), 1.66 (s, 3H), 0.92 (s, 3H), 0.80 (s, 3H), 0.78 (s, 3H), 0.75 (s, 
3H), 0.68 (s, 3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 176.6, 176.3, 171.9, 166.9, 
150.9, 146.1, 144.9, 133.5, 130.0, 129.7, 128.9, 124.7, 123.4, 109.3, 81.4, 55.6, 55.5, 
52.6, 50.4, 50.1, 46.9, 46.8, 42.4, 40.6, 38.4, 38.1, 37.8, 37.7, 37.0, 34.2, 34.0, 33.3, 30.8, 
29.4, 29.3, 29.1, 27.8, 25.5, 23.6, 20.9, 19.4, 18.1, 16.5, 16.1, 15.7, 14.6; ESIMS: m/z 
811.65 [100%, (M+H)+], HRMS-ESI: calculated for C48H66N4O7 [M+H]
+ 811.5004, 
found 811.5038. 
 
 
Preparation of succinic acid hemiester 64b: Procedure similar to that of 64a. Yield: 80%; 
cream color solid; mp 130 – 132 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.60 (s, 
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1H), 7.33 – 7.43 (m, 5H), 6.99 (s, 1H), 6.29 (m, 1H), 5.33 (s, 2H), 4.72 (s, 1H), 4.58 (s, 
1H), 4.39 – 4.50 (m, 3H), 3.55 – 3.70 (m, 2H), 3.07 – 3.18 (m, 1H), 3.05 (brs, 3H), 2.70 
(m, 1H), 2.29 – 2.77 (m, 8H), 2.24 – 2.40 (m, 4H), 0.63 – 1.94 (m, 23H), 1.66 (s, 3H), 
0.92 (s, 3H), 0.80 (s, 6H), 0.76 (s, 3H), 0.75 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 
(ppm) 176.5, 176.3, 172.6, 150.8, 145.4, 135.1, 133.8, 129.8, 129.7, 128.9, 128.7, 113.9, 
109.5, 80.9, 55.6, 55.4, 50.4, 50.1, 48.6, 46.8, 43.8, 42.4, 40.7, 38.3, 38.2, 37.8, 37.7, 
37.0, 34.6, 34.2, 33.4, 30.8, 30.1, 30.0, 29.7, 29.4, 27.9, 25.5, 23.6, 20.9, 19.4, 18.1, 16.5, 
16.2, 15.8, 14.6; ESIMS: m/z calculated for C52H76N6O6 (M+H)
+ 881.59, found 881.58. 
 
 
Preparation of succinic acid hemiester 64c: Procedure similar to that of 64a. Yield: 83%; 
cream color solid; mp 142 – 145 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.61 (s, 1H), 
7.36 – 7.44 (m, 5H), 6.88 (s, 1H), 6.58 (t, J = 5.7 Hz, 1H), 5.34 (s, 2H), 4.72 (s, 1H), 4.58 
(s, 1H), 4.43 – 4.50 (m, 3H), 3.73 (brs, 4H) 3.12 (dt, J = 5.4, 11.0 Hz, 1H), 2.57 – 2.65 
(m, 4H), 2.26 – 2.53 (m, 5H), 2.36 (s, 3H), 0.72 – 1.96 (m, 23H), 1.67 (s, 3H), 0.93 (s, 
3H), 0.82 (s, 3H), 0.81 (s, 3H), 0.77 (s, 3H), 0.74 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 
(ppm) 176.6, 175.8, 172.3, 168.9, 150.8, 145.4, 135.1, 133.7, 129.1, 128.9, 128.9, 128.7, 
123.5, 109.4, 81.1, 55.6, 55.4, 53.8, 50.4, 50.1, 48.6, 46.8, 44.7, 42.4, 40.7, 38.4, 38.1, 
37.8, 37.7, 37.0, 34.5, 34.2, 33.4, 30.8, 29.8, 29.6, 29.6, 29.4, 27.9, 25.5, 23.6, 
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20.9, 19.4, 18.1, 16.5, 16.2, 15.8, 14.6; ESIMS: m/z calculated for C52H74N6O6 (M+H)
+ 
879.57, found 879.65. 
 
Preparation of succinic acid hemiester 64d: Procedure similar to that of 64a. Yield: 82%; 
white solid; mp 114 – 116 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 9.68 (s, 1H), 7.91 (s, 
1H), 7.60 (s, 1H), 7.27 – 7.39 (m, 3H), 7.20 – 7.25 (m, 2H), 6.66 (t, J = 5.5 Hz, 1H), 4.72 
(s, 1H), 4.58 (s, 1H), 4.40 – 4.57 (m, 5H), 3.73 – 3.85 (m, 2H), 3.34 (s, 2H), 3.12 (dt, J = 
4.2, 10.8 Hz, 1H), 2.40 – 2.68 (m, 8H), 2.34 (m, 1H), 2.28 (s, 6H), 2.05 (s, 3H), 0.72 – 
1.98 (m, 23H), 1.66 (s, 3H), 0.92 (s, 3H), 0.81 (s, 9H), 0.77 (s, 3H); 13C NMR (101 MHz, 
CDCl3): δ (ppm) 176.5 (2C), 172.7, 168.5, 150.8, 145.3, 140.3, 135.5, 130.3, 129.0, 
128.3, 127.9, 123.0, 109.4, 80.9, 55.6, 55.4, 55.2, 53.9, 53.5, 53.1, 50.6, 50.5, 50.1, 49.4, 
46.7, 44.1, 42.4, 41.4, 40.7, 39.6, 38.4, 38.2, 37.8, 37.7, 37.1, 34.6, 34.2, 33.4, 30.9, 29.4, 
27.9, 25.5, 23.7, 20.9, 19.4, 18.1, 16.5, 16.2, 15.8, 14.6; ESIMS: m/z calculated for 
C54H81N7O6 (M+H)
+ 924.63, found 924.70. 
 
Preparation of succinic acid hemiester 64e: Procedure similar to that of 64a. Yield: 
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84%; cream color solid; mp 132 – 134 °C; 1H NMR (400 MHz, CDCl3): δ 9.64 (m, 1H), 
7.94 (s, 1H), 7.64 (s, 1H), 7.28 – 7.40 (m, 3H), 7.19 – 7.23 (m, 2H), 6.52 (t, J = 5.0 Hz, 
1H), 4.72 (s, 1H), 4.59 (s, 1H), 4.38 – 4.51 (m, 5H), 3.88 – 3.92 (m, 2H), 3.38 (s, 2H), 
3.11 (dt, J = 4.4, 11.0 Hz, 1H), 2.40 – 2.76 (m, 10H), 2.44 (s, 3H), 2.33 (m, 3H), 0.71 – 
1.95 (m, 23H), 1.67 (s, 3H), 0.93 (s, 3H), 0.81 (s, 6H), 0.79 (s, 3H), 0.75 (s, 3H); 13C 
NMR (101 MHz, CDCl3): δ 176.7 (2C), 172.6, 168.5, 150.7, 145.7, 141.5, 134.9, 128.9, 
128.7, 128.5, 128.3, 123.5, 109.5, 80.9, 55.6, 55.4, 54.2, 53.3, 50.6, 50.4, 50.1, 50.0, 46.8, 
44.0, 42.4, 40.7, 39.0, 38.3, 38.2, 37.8, 37.7, 37.1, 34.6, 34.3, 33.4, 30.8, 29.7, 29.4, 27.9, 
25.5, 23.6, 20.9, 19.4, 18.1, 16.5, 16.2, 15.8, 14.6; ESIMS: m/z  calculated for 
C54H79N7O6 (M+H)
+ 922.62, found 922.75. 
 
 
Preparation of succinic acid hemiester 64f: Procedure similar to that of 64a. Yield: 81%; 
yellow solid; mp 141 – 144 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.64 (d, J = 15.6 
Hz, 1H), 7.63 (s, 1H), 7.46 – 7.52 (m, 2H), 7.34 – 7.38 (m, 3H), 6.60 – 6.69 (m, 1H), 6.40 
(d, J = 15.5 Hz, 1H), 6.26 – 6.34 (m, 1H), 4.70 (s, 1H), 4.57 (s, 1H), 4.39 – 4.54 (m, 5H), 
3.80 – 3.97 (m, 2H), 3.09 (dt, J = 4.1, 11.0 Hz, 1H), 2.59 – 2.70 (m, 4H), 2.22 – 2.33 (m, 
1H), 0.66 – 1.91 (m, 23H), 1.65 (s, 3H), 0.91 (s, 3H), 0.80 (s, 3H), 0.79 (s, 6H), 0.71 (s, 
3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 176.9 (2C), 172.2, 166.6, 150.7, 145.3, 
141.8, 134.5, 129.9, 128.8, 127.9, 123.6, 119.9, 109.5, 81.4, 55.6, 55.4, 50.4, 50.0, 49.8, 
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46.8, 42.4, 40.7, 39.5, 38.3, 38.1, 37.8, 37.7, 37.0, 34.3, 34.2, 33.3, 30.8, 29.6, 29.3, 27.8, 
25.5, 23.6, 20.9, 19.4, 18.1, 16.5, 16.2, 15.7, 14.6; ESIMS: m/z 810.75 [100%, (M+H)+], 
HRMS-ESI: calculated for C48H67N5O6 [M+H]
+ 832.4984, found 832.5026. 
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Chapter 4 
Spectral Characterization 
 
Figure 28. 400 MHz 1H NMR of Compound 56 in CDCl3 
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Figure 29. 101 MHz 13C NMR of Compound 56 in CDCl3  
  
58 
 
Figure 30. 400 MHz 1H NMR of Compound 57 in DMSO-d6  
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Figure 31. 101 MHz 13C NMR of Compound 57 in DMSO-d6  
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Figure 32. 400 MHz 1H NMR of Compound 58 in CDCl3  
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Figure 33. 101 MHz 13C NMR of Compound 58 in CDCl3  
  
62 
 
Figure 34. 400 MHz 1H NMR of Compound 59 in CDCl3  
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Figure 35. 101 MHz 13C NMR of Compound 59 in CDCl3  
  
64 
 
Figure 36. 400 MHz 1H NMR of Compound 51b in CDCl3  
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Figure 37. 101 MHz 13C NMR of Compound 51b in CDCl3  
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Figure 38. 400 MHz 1H NMR of Compound 51c in CDCl3  
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Figure 39. 101 MHz 13C NMR of Compound 51c in CDCl3  
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Figure 40. 400 MHz 1H NMR of Compound 51d in CDCl3  
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Figure 41. 101 MHz 13C NMR of Compound 51d in CDCl3  
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Figure 42. 400 MHz 1H NMR of Compound 51e in CDCl3  
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Figure 43. 101 MHz 13C NMR of Compound 51e in CDCl3  
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Figure 44. 400 MHz 1H NMR of Compound 62a in CDCl3  
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Figure 45. 101 MHz 13C NMR of Compound 62a in CDCl3  
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Figure 46. 400 MHz 1H NMR of Compound 62b in CDCl3  
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Figure 47. 101 MHz 13C NMR of Compound 62b in CDCl3  
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Figure 48. 400 MHz 1H NMR of Compound 62c in CDCl3  
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Figure 49. 101 MHz 13C NMR of Compound 62c in CDCl3  
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Figure 50. 400 MHz 1H NMR of Compound 62d in CDCl3  
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Figure 51. 101 MHz 13C NMR of Compound 62d in CDCl3  
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Figure 52. 400 MHz 1H NMR of Compound 62e in CDCl3  
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Figure 53. 101 MHz 13C NMR of Compound 62e in CDCl3  
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Figure 54. 400 MHz 1H NMR of Compound 62f in CDCl3  
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Figure 55. 101 MHz 13C NMR of Compound 62f in CDCl3  
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Figure 56. 400 MHz 1H NMR of Compound 63a in CDCl3  
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Figure 57. 101 MHz 13C NMR of Compound 63a in CDCl3  
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Figure 58. 400 MHz 1H NMR of Compound 63b in CDCl3  
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Figure 59. 101 MHz 13C NMR of Compound 63b in CDCl3  
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Figure 60. 400 MHz 1H NMR of Compound 63c in CDCl3  
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Figure 61. 101 MHz 13C NMR of Compound 63c in CDCl3  
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Figure 62. 400 MHz 1H NMR of Compound 63d in CDCl3  
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Figure 63. 101 MHz 13C NMR of Compound 63d in CDCl3  
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Figure 64. 400 MHz 1H NMR of Compound 63e in CDCl3  
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Figure 65. 101 MHz 13C NMR of Compound 63e in CDCl3  
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Figure 66. 400 MHz 1H NMR of Compound 63f in CDCl3  
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Figure 67. 101 MHz 13C NMR of Compound 63f in CDCl3  
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Figure 68. 400 MHz 1H NMR of Compound 64a in CDCl3  
  
97 
 
 
Figure 69. 101 MHz 13C NMR of Compound 64a in CDCl3  
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Figure 70. 400 MHz 1H NMR of Compound 64b in CDCl3  
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Figure 71. 101 MHz 13C NMR of Compound 64b in CDCl3  
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Figure 72. 400 MHz 1H NMR of Compound 64c in CDCl3  
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Figure 73. 101 MHz 13C NMR of Compound 64c in CDCl3  
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Figure 74. 400 MHz 1H NMR of Compound 64d in CDCl3  
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Figure 75. 101 MHz 13C NMR of Compound 64d in CDCl3  
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Figure 76. 400 MHz 1H NMR of Compound 64e in CDCl3  
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Figure 77. 101 MHz 13C NMR of Compound 64e in CDCl3  
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Figure 78. 400 MHz 1H NMR of Compound 64f in CDCl3  
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Figure 79. 101 MHz 13C NMR of Compound 64f in CDCl3 
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